elosulfase alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	4999	9025-60-9

Description:

Molecule

Description

Synonyms:

elosulfase alfa
vimizim
BMN 110
rhGALNS
EC 3.1.6.4
BMN-110

BMN-100 and BMN 110 are recombinant GALNS; RefSeq NM_000512

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
20	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 28, 2014	EMA
Feb. 14, 2014	FDA	BIOMARIN PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Knee deformity	55.85	47.25	10	648	1335	63487029
Spinal cord compression	50.13	47.25	11	647	4137	63484227

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Spinal cord compression	61.70	49.61	13	360	3962	34952596

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Spinal cord compression	86.94	41.08	19	894	6358	79737117
Urticaria	63.03	41.08	34	879	185167	79558308
Knee deformity	61.87	41.08	11	902	1274	79742201
Pyrexia	51.86	41.08	50	863	678659	79064816
Oxygen saturation decreased	47.50	41.08	25	888	129022	79614453

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A16AB12	ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Enzymes
FDA CS	M0000794	alpha-Glucosidases
FDA EPC	N0000175823	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Mucopolysaccharidosis, MPS-IV-A	indication	7259005	DOID:0111391

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D10333	KEGG_DRUG
4033117	VUID
N0000190127	NUI
4033117	VANDF
CHEMBL2108676	ChEMBL_ID
C102295	MESH_SUPPLEMENTAL_RECORD_UI
7392	IUPHAR_LIGAND_ID
DB09051	DRUGBANK_ID
1489914	RXNORM
213108	MMSL
30194	MMSL
d08244	MMSL
015387	NDDF
702395005	SNOMEDCT_US
716640004	SNOMEDCT_US
C3817397	UMLSCUI
9686	INN_ID
ODJ69JZG85	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VIMIZIM	HUMAN PRESCRIPTION DRUG LABEL	1	68135-100	INJECTION, SOLUTION, CONCENTRATE	5 mg	INTRAVENOUS	BLA	23 sections
VIMIZIM	HUMAN PRESCRIPTION DRUG LABEL	1	68135-100	INJECTION, SOLUTION, CONCENTRATE	5 mg	INTRAVENOUS	BLA	23 sections